Korean Drug Co. Ltd Cash Flow Quality Index
Korean Drug Co. Ltd cash flow quality index. Korean Drug Co. Ltd (014570) has a Cash Flow Quality Index of 5.49x as of March 2026. Operating cash flow of ₩6.60 Billion exceeds net income of ₩1.20 Billion, indicating high earnings quality where cash backs reported profits. See 014570 financial flexibility index to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of Korean Drug Co. Ltd (2014–2025)
Cash flow quality index of Korean Drug Co. Ltd from 2014 to 2025. Historical Cash Flow Quality Index for Korean Drug Co. Ltd across 11 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore Korean Drug Co. Ltd (014570) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Korean Drug Co. Ltd Cash Flow Quality Index by Year (2014–2025)
Korean Drug Co. Ltd cash flow quality index by year from 2014 to 2025. Year-by-year earnings quality comparison for Korean Drug Co. Ltd. For the full cash flow conversion analysis, see Korean Drug Co. Ltd operating cash flow efficiency.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 2.01x | ₩13.11 Billion | ₩6.51 Billion | ▲ +23.8% |
| 2024 | 1.63x | ₩4.87 Billion | ₩3.00 Billion | ▲ +224.7% |
| 2022 | 0.50x | ₩5.91 Billion | ₩11.81 Billion | ▼ -48.6% |
| 2021 | 0.97x | ₩8.81 Billion | ₩9.04 Billion | ▼ -41.9% |
| 2020 | 1.68x | ₩12.33 Billion | ₩7.36 Billion | ▲ +5.1% |
| 2019 | 1.59x | ₩6.21 Billion | ₩3.90 Billion | ▲ +80.7% |
| 2018 | 0.88x | ₩5.79 Billion | ₩6.56 Billion | ▲ +823.6% |
| 2017 | 0.10x | ₩447.20 Million | ₩4.68 Billion | ▼ -87.8% |
| 2016 | 0.78x | ₩3.96 Billion | ₩5.05 Billion | ▼ -77.3% |
| 2015 | 3.46x | ₩6.13 Billion | ₩1.77 Billion | ▲ +66.7% |
| 2014 | 2.07x | ₩4.46 Billion | ₩2.15 Billion | — |